|
|
||||||||
,3,1 Pennington Biomedical Research Center, Human Genomics Laboratory, Baton Rouge, Louisiana 70808-4124; 2 Department of Prevention, Rehabilitation, and Sports Medicine, University of Freiburg, 79106 Freiburg, Germany; 3 Physical Activity Sciences Laboratory, Laval University, Ste-Foy, Québec G1K 7P4; Canada; 4 Kuopio Research Institute of Exercise Medicine, Department of Physiology, University of Kuopio, and Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, 70100 Kuopio, Finland; and 5 Department of Physiology and Department of Physical Medicine, Rehabilitation, and Sports Medicine, University of Puerto Rico School of Medicine, San Juan, Puerto Rico 00936
| |
ABSTRACT |
|---|
|
|
|---|
Several
studies have reported that the insertion (I) allele of the
angiotensin-converting enzyme (ACE) I/deletion (D) polymorphism is associated with enhanced responsiveness to endurance training and is
more common in endurance athletes than in sedentary controls. We tested
the latter hypothesis in a cohort of 192 male endurance athletes with
maximal oxygen uptake
75
ml · kg
1 · min
1
and 189 sedentary male controls. The ACE ID polymorphism in
intron 16 was typed with the three-primer polymerase chain reaction
method. Both the genotype (P = 0.214) and allele
(P = 0.095) frequencies were similar in the athletes and the
controls. Further analyses in the athletes revealed no excess of the I
allele among the athletes within the highest quartile (> 80 ml · kg
1 · min
1)
or decile (>83
ml · kg
1 · min
1)
of maximal oxygen uptake. These data from the GENATHLETE cohort do
not support the hypothesis that the ACE ID polymorphism is associated with a higher cardiorespiratory endurance performance level.
genetics; sports; endurance performance; insertion/deletion
| |
INTRODUCTION |
|---|
|
|
|---|
PERFORMANCE IN ENDURANCE SPORTS is a multifactorial
phenotype, influenced by several factors, such as physique,
biomechanical, physiological, metabolic, behavioral, psychological, and
social characteristics. The effects of environmental factors on
endurance performance are well documented, but a considerable amount of data from twin and family studies have shown that cardiorespiratory fitness, for which maximal oxygen consumption
(
O2 max) is
traditionally recognized as the gold standard, is also influenced by
genetic factors. For instance, in pairs of monozygotic twins, the
O2 max response to
standardized training programs in a series of experiments was
characterized by six to nine times more variance between genotypes (between pairs of twins) than within genotypes (within pairs of twins)
(6). Similarly, in the sedentary state, the intrapair resemblance for
cardiorespiratory endurance phenotypes has been significantly higher in
monozygotic twins than in dizygotic twins, with heritability estimates
ranging from 25 to 66% (7, 11, 21, 40). Family studies have suggested
a genetic effect of ~25-40% for
O2 max
adjusted for age, gender, and body mass or body composition (18, 20,
25). In the HERITAGE Family Study cohort, maximal
heritabilities of 51 and 47% were observed for the
O2 max in the sedentary
state (5) and its response to 20 wk of endurance training (4), respectively.
Because of the polygenic nature of endurance performance phenotypes, it
is unlikely that the genetic component of these traits will be
explained by DNA sequence variation at only a few genes. It is more
likely that several gene loci, each with a small but significant
contribution, will be responsible for this genetic component. A limited
number of candidate genes have been tested so far in this context. For
example, data from the HERITAGE Family Study have revealed
statistically significant associations between the training responses
of cardiorespiratory fitness-related phenotypes and skeletal
muscle-specific creatine kinase and
Na+-K+-ATPase
2 gene polymorphisms (29, 33,
34).
Over the past 2 yr, some studies have suggested that the DNA sequence
variation at the gene locus encoding angiotensin-converting enzyme
(ACE) is associated with physical performance. A series of
papers based on a cohort of British military recruits have found that
the insertion (I) allele and the II genotype of the I/deletion (D)
polymorphism in intron 16 of the ACE gene were associated with
a lower training-induced cardiac hypertrophy (23) and greater increases
in performance after a 10-wk physical training program (22, 24). A
higher frequency of the I allele and the II genotype was reported in
Australian rowers (12) and British mountaineers (24) than in sedentary
controls. In a small group of postmenopausal women, the homozygotes for
the I allele had higher
O2 max than did the
other genotypes (13). In British Olympic-standard runners, an increase
in frequency of the I allele as a function of distance run was
reported, although the association disappeared when the analysis was
repeated only in Caucasian athletes (26).
However, in a cohort of 724 sedentary subjects from the HERITAGE Family
Study, we found no support for the hypothesis that the ACE I
allele was associated with a greater trainability of fitness-related
phenotypes (30). Both in blacks (n = 248) and in Caucasians
(n = 476), all of the 26 phenotypes measured in the sedentary
state were similar across the ACE ID genotypes. Of the training
response phenotypes, statistically significant associations were found
only in Caucasian offsprings, but in sharp contrast to previous
studies, the DD homozygotes showed greater increases in oxygen
consumption and power output phenotypes than did the other genotypes.
Moreover, in the HERITAGE Family Study, a genomic scan for
O2 max in the
sedentary state and in its response to training provided no
evidence of linkage with the ACE gene locus or any other
regions on chromosome 17 (8). Similarly, in a group of 120 Australian
endurance athletes (41) and a cohort of 404 British Olympic-standard
athletes (26), the ACE ID genotype and allele frequencies did
not differ from those of sedentary control groups. In a cohort of 80 Finnish endurance athletes, frequencies of the II, ID, and DD genotypes
were 0.225, 0.475 and 0.300, respectively, i.e., identical to the
frequencies reported in general population (14, 16).
Because the previous positive findings have emerged mainly from studies with relatively small sample sizes, and because the results derived from sedentary subjects may not necessarily reflect the situation in highly trained athletes, we investigated whether the ACE ID polymorphism was associated with endurance athlete status in the GENATHLETE cohort comprising 192 elite endurance athletes and 189 sedentary controls.
| |
METHODS |
|---|
|
|
|---|
Subjects.
Altogether, 192 male endurance athletes with a
O2 max of
at least 75 ml · kg
1 · min
1
[mean 78.6 ± 3.2 (SD)
ml · kg
1 · min
1,
range 75.0-92.9
ml · kg
1 · min
1]
and 189 sedentary male controls
[
O2 max 36.4 ± 7.4 (SD)
ml · kg
1 · min
1,
range 23.1-50.0
ml · kg
1 · min
1]
were available for the present study. The athletes were recruited from
Canada (n = 51), Germany (n = 63), Finland (n = 42), and the United States (n = 36), and they
represented the following endurance sports: cross-country skiing
(n = 59), biathlon (n = 40), nordic combined (n = 2), long-distance running (n = 20), middle-distance running
(n = 19), and road cycling (n = 48). All the athletes
had been competing at the national or international level for several
years. The control group comprised healthy sedentary subjects from the
same geographic areas as the athletes. The controls either were derived
from the previous studies performed in our laboratories (3, 31) or were
recruited specifically for the GENATHLETE study (Germany). The number
of athletes and controls from each country was approximately equal. All
the subjects were Caucasians. Informed written consent was obtained
from all subjects.
O2 max of the
athletes was determined in the course of incremental exercise tests on
cycle ergometers (cyclists) or motor-driven treadmills (skiers and
runners) when the athletes were at their peak. The
O2 max of the
controls was assessed during an incremental cycle ergometer test.
Genotype determinations. Genomic DNA was isolated from lymphoblastoid cell lines or white blood cells following a standard protocol (37). The ACE ID polymorphism was typed with a PCR-based method using three primers as previously described (10). The final reaction mixture of 15 µl contained 100 ng of genomic DNA, 3.0 mM MgCl2, 200 µM each 2'deoxynucleoside 5'-triphosphates, 300 nM primers flanking the insertion sequence, 140 nM nested primer, 4.7% DMSO, and 1.0 U of Taq polymerase (Pharmacia Biotech, Baie d'Urfé, PQ). The PCR protocol (model 9600 thermal cycler, Perkin Elmer, Norwalk, CT) consisted of one cycle at 94°C for 3 min, 55°C for 1 min, and 72°C for 1 min, followed by 35 cycles at 94°C for 30 s, 55°C for 30 s, 72°C for 45 s, and finally 1 cycle at 72°C for 10 min. The PCR products were separated on 3.5% agarose gel and visualized under ultraviolet light after ethidium bromide staining.
Statistical methods.
All statistical analyses were done with the version 6.12 of the SAS
statistical software package (SAS Institute, Cary, NC). A
2 test was used to confirm that the observed genotype
frequencies were in a Hardy-Weinberg equilibrium and to compare the
ACE ID allele and genotype frequencies between athletes and
controls, as well as between different sports and places of origin.
Differences in
O2 max, body weight,
and height among the athletes from different sports were tested with an
analysis of variance by using the general linear model procedure of the
SAS package.
| |
RESULTS |
|---|
|
|
|---|
Among the athletes,
O2 max and height were
similar across sports (P = 0.246 and 0.715, respectively) and
places of origin (P = 0.682 and 0.057, respectively), whereas
skiers and cyclists were heavier than runners [70.8 ± 0.7 (SE)
and 71.0 ± 1.2 vs. 64.7 ± 1.3 kg, respectively; P = 0.0002]. However, the ACE ID genotype frequencies did not
differ among the sports, with values of 0.248, 0.495, and 0.257 in
skiers, 0.256, 0.436 and 0.308 in runners, and 0.292, 0.438, and 0.271 in cyclists for the II, ID, and DD genotypes, respectively
(
2 = 0.85, df = 4, P = 0.932). The genotype
frequencies were also similar across countries of origin for both
athletes and controls (0.223, 0.417, and 0.360 in Canada, 0.262, 0.469, and 0.269 in Germany, 0.184, 0.513, and 0.303 in Finland, and 0.250, 0.583, and 0.167 in the United States for the II, ID, and DD,
genotypes, respectively;
2 = 7.66, df = 6, P = 0.264).
No differences were observed in the allele and genotype frequencies of
the ACE ID polymorphism between athletes and controls (Table
1). In both groups, the
genotype frequencies were in Hardy-Weinberg equilibrium. The GENATHLETE
study has been designed as a case-control study, but because some
previous studies have reported that the ACE I allele was
associated with a high performance level, we tested whether a similar
trend was present among our endurance athletes. For this purpose, two
O2 max cutoffs were
used to classify the athletes: 80 ml · kg
1 · min
1
represented a cutoff for the highest
O2 max quartile
(n = 52), and 83 ml · kg
1 · min
1
was used to define the highest decile of
O2 max
(n = 23). With both cutoffs, we found no evidence for the
accumulation of the I allele or the II genotype among the athletes with
the highest
O2 max
values. The frequencies of the II, ID, and DD genotypes, respectively,
were 0.327, 0.385, and 0.288 in the highest quartile and were 0.261, 0.391, and 0.348 in the highest decile (Fig.
1), i.e., similar to those observed in the
athletes with a lower
O2 max.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
The results of the present study do not support the hypothesis that variation in the ACE gene locus has an influence on human cardiorespiratory endurance performance. The seemingly controversial results reported thus far may be due to factors related to sample sizes, study designs, and phenotype measurements. The positive findings have emerged from relatively small cohorts (n from 25 to 91), whereas studies with large number of subjects (n from 120 to 724) and rigorously controlled phenotype measurements and exercise training programs, such as the HERITAGE Family Study (30), the study by Taylor et al. (41), and the present study, have yielded negative results. A similar effect of sample size has been observed in the studies dealing with the associations between the ACE ID polymorphism and various cardiovascular disorders. The studies based on large numbers of subjects have generally failed to confirm the positive findings arising from smaller cohorts (1, 19, 39, 44). Moreover, two meta-analyses have detected a publication bias toward positive findings from smaller studies (36, 39), a finding that may also be relevant for the topic of the ACE genotype and physical performance.
Other relevant features of the previous studies are that the
associations between the ACE ID polymorphism and physical
performance were mainly tested post hoc (i.e., the studies were not
originally designed to address such questions) and that the phenotypes
were not well standardized. An exception is the study by Gayagay et al.
(12) where the athletes were selected from a clearly defined group of
Australian Olympic-level rowers. In the present study, instead of
selecting a specific sport, we employed a preset
O2 max criterion that
the athletes had to meet to be included in the study. We were not able
to replicate the findings of Gayagay et al. One explanation for the
different outcome may be that rowers represent a special group among
endurance athletes. Rowing employs mainly upper body musculature,
whereas the performance level in other endurance sports is mostly
dependent on the function of the muscles of the lower body or both the
lower and upper body. Another potential explanation could be the
smaller sample size of rowers.
It has been suggested that the ACE I allele is associated with
a high level of physical performance (24). Along the lines of this
hypothesis we did a subgroup analysis in the elite endurance athletes
group. Even in the athletes with
O2 max values over 83 ml · kg
1 · min
1
(highest decile), we found no trend for an excess of the I allele or a
low number of DD homozygotes (Fig. 1). In our opinion, these findings
argue against the idea that the ACE ID polymorphism is associated with extraordinary cardiorespiratory endurance performance. However, it remains to be confirmed whether the ACE ID
polymorphism is specifically associated with an adaptation to perform
at high altitude. In Native South Americans it does not seem to be the case (35), but similar data in Caucasians are still missing.
Although an association between the ACE ID genotype and
circulating ACE levels has been established (32, 42), there are surprisingly few data on the physiological mechanisms for the proposed
associations between the ACE ID polymorphism and the various
phenotypes. Systemic angiotensin II levels and blood pressure seem to
be unaffected by the ACE ID genotype-related variation in
plasma ACE levels (17). In addition, treatment with ACE inhibitors causes a drastic decrease in ACE activity and angiotensin II levels but
has no effect on endurance performance in healthy or mildly hypertensive subjects (2, 27, 28). It has been suggested that the
greater ACE II genotype frequency in endurance athletes could
reflect the selection of individuals with a "healthier" cardiovascular system and, thus a higher aerobic capacity (12, 24, 26).
However, the results by Taylor et al. (41), our findings based on a
large group of endurance athletes with documented high
O2 max level, and the
controversial reports on the associations between the ACE ID
genotype and various cardiovascular phenotypes cast doubts over this
hypothesis. Nevertheless, it is possible that an interaction with other
genetic, physiological, or environmental factors is required for the
expression of the ACE ID genotype effects. This possibility is
underlined by the finding that the influence of the ACE ID
genotype on plasma angiotensin II levels is detected when the
circulating substrate concentrations are increased by angiotensin I
infusion (43).
In addition to the endurance performance traits, the data on the effects of the ACE ID polymorphism on various cardiovascular phenotypes in general are far from clear. The interpretation of the data is further complicated by the fact that even the studies with positive results have reported that the associations seemed to be restricted to a special subgroup of the cohort, such as subjects with low levels of cardiovascular risk factors (9). Moreover, the reports showing that, unlike one would assume, the D allele and DD genotype were more common in centenarians (38) and were associated with a lower risk of Alzheimer's disease (15) further add to the confusion. Thus it is obvious that more studies are needed to fully understand the function of the ACE gene and the possible effects of its DNA sequence variation on various biological traits.
In conclusion, the results from the GENATHLETE cohort do not support the hypothesis that the ACE ID genotype is a determinant of cardiorespiratory endurance performance.
| |
ACKNOWLEDGEMENTS |
|---|
We acknowledge the inspiration and contributions to this paper of Jean-Aimé Simoneau, PhD, who died on August 27, 1999, after a prolonged illness.
| |
FOOTNOTES |
|---|
Thanks are expressed to Drs. N. Gledhill, G. Huber, E. Jacob, T. Noakes, G. Phillips, K. W. Rundell, H. K. Rusko, and J. Stray-Gundersen, who kindly provided some of the DNA samples from the athletes.
This work was supported by Fonds pour la Formation de Chercheurs et d'Aide à la Recherche Quebec Grant ER-2449 and National Sciences and Engineering Research Council of Canada Grant OPG-0042791.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: C. Bouchard, Pennington Biomedical Research Center, 6400 Perkins Rd., Baton Rouge, LA 70808-4124. (E-mail: bouchac{at}pbrc.edu).
Received 21 October 1999; accepted in final form 18 December 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Agerholm-Larsen, B,
Nordestgaard BG,
Steffensen R,
Sorensen TI,
Jensen G,
and
Tybjaerg-Hansen A.
ACE gene polymorphism: ischemic heart disease and longevity in 10,150 individuals. A case-referent and retrospective cohort study based on the Copenhagen City Heart Study.
Circulation
95:
2358-2367,
1997
2.
Aldigier, JC,
Huang H,
Dalmay F,
Lartigue M,
Baussant T,
Chassain AP,
Leroux-Robert C,
and
Galen FX.
Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans.
J Cardiovasc Pharmacol
21:
289-295,
1993[ISI][Medline].
3.
Bouchard, C.
Genetic epidemiology, association and sib-pair linkage: results from the Quebec Family Study.
In: Molecular and Genetic Aspects of Obesity, edited by Bray G A.,
and Ryan D. H.. Baton Rouge: Louisiana State Univ. Press, 1996, p. 470-481.
4.
Bouchard, C,
An P,
Rice T,
Skinner JS,
Wilmore JH,
Gagnon J,
Perusse L,
Leon AS,
and
Rao DC.
Familial aggregation of
O2 max response to exercise training: results from the HERITAGE Family Study.
J Appl Physiol
87:
1003-1008,
1999
5.
Bouchard, C,
Daw EW,
Rice T,
Perusse L,
Gagnon J,
Province MA,
Leon AS,
Rao DC,
Skinner JS,
and
Wilmore JH.
Familial resemblance for
O2 max in the sedentary state: the HERITAGE family study.
Med Sci Sports Exerc
30:
252-258,
1998[ISI][Medline].
6.
Bouchard, C,
Dionne FT,
Simoneau JA,
and
Boulay MR.
Genetics of aerobic and anaerobic performances.
Exerc Sport Sci Rev
20:
27-58,
1992[Medline].
7.
Bouchard, C,
Lesage R,
Lortie G,
Simoneau JA,
Hamel P,
Boulay MR,
Perusse L,
Theriault G,
and
Leblanc C.
Aerobic performance in brothers, dizygotic and monozygotic twins.
Med Sci Sports Exerc
18:
639-646,
1986[ISI][Medline].
8.
Bouchard, C,
Rankinen T,
Chagnon YC,
Rice T,
Perusse L,
Gagnon J,
Borecki I,
An P,
Leon AS,
Skinner JS,
Wilmore JH,
Province M,
and
Rao DC.
Genomic scan for maximal oxygen uptake and its response to training in the HERITAGE Family Study.
J Appl Physiol
88:
551-559,
2000
9.
Cambien, F,
Poirier O,
Lecerf L,
Evans A,
Cambou JP,
Arveiler D,
Luc G,
Bard JM,
Bara L,
Ricard S,
Tiret L,
Amouyel P,
Alhenc-Gelas F,
and
Soubrier F.
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction.
Nature
359:
641-644,
1992[Medline].
10.
Evans, AE,
Poirier O,
Kee F,
Lecerf L,
McCrum E,
Falconer T,
Crane J,
O'Rourke DF,
and
Cambien F.
Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease.
QJM
87:
211-214,
1994
11.
Fagard, R,
Bielen E,
and
Amery A.
Heritability of aerobic power and anaerobic energy generation during exercise.
J Appl Physiol
70:
357-362,
1991
12.
Gayagay, G,
Yu B,
Hambly B,
Boston T,
Hahn A,
Celermajer DS,
and
Trent RJ.
Elite endurance athletes and the ACE I allele
the role of genes in athletic performance.
Hum Genet
103:
48-50,
1998[ISI][Medline].
13.
Hagberg, JM,
Ferrell RE,
McCole SD,
Wilund KR,
and
Moore GE.
O2 max is associated with ACE genotype in postmenopausal women.
J Appl Physiol
85:
1842-1846,
1998
14.
Karjalainen, J,
Kujala UM,
Stolt A,
Mantysaari M,
Viitasalo M,
Kainulainen K,
and
Kontula K.
Angiotensinogen gene M235T polymorphism predicts left ventricular hypertrophy in endurance athletes.
J Am Coll Cardiol
34:
494-499,
1999
15.
Kehoe, PG,
Russ C,
McIlory S,
Williams H,
Holmans P,
Holmes C,
Liolitsa D,
Vahidassr D,
Powell J,
McGleenon B,
Liddell M,
Plomin R,
Dynan K,
Williams N,
Neal J,
Cairns NJ,
Wilcock G,
Passmore P,
Lovestone S,
Williams J,
and
Owen MJ.
Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease.
Nat Genet
21:
71-72,
1999[ISI][Medline].
16.
Kiema, TR,
Kauma H,
Rantala AO,
Lilja M,
Reunanen A,
Kesaniemi YA,
and
Savolainen MJ.
Variation at the angiotensin-converting enzyme gene and angiotensinogen gene loci in relation to blood pressure.
Hypertension
28:
1070-1075,
1996
17.
Lachurie, ML,
Azizi M,
Guyene TT,
Alhenc-Gelas F,
and
Menard J.
Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects.
Circulation
91:
2933-2942,
1995
18.
Lesage, R,
Simoneau JA,
Jobin J,
Leblanc J,
and
Bouchard C.
Familial resemblance in maximal heart rate, blood lactate and aerobic power.
Hum Hered
35:
182-189,
1985[ISI][Medline].
19.
Lindpaintner, K,
Pfeffer MA,
Kreutz R,
Stampfer MJ,
Grodstein F,
LaMotte F,
Buring J,
and
Hennekens CH.
A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease.
N Engl J Med
332:
706-711,
1995
20.
Lortie, G,
Bouchard C,
Leblanc C,
Tremblay A,
Simoneau JA,
Theriault G,
and
Savoie JP.
Familial similarity in aerobic power.
Hum Biol
54:
801-812,
1982[ISI][Medline].
21.
Maes, HH,
Beunen GP,
Vlietinck RF,
Neale MC,
Thomis M,
Vanden Eynde B,
Lysens R,
Simons J,
Derom C,
and
Derom R.
Inheritance of physical fitness in 10-yr-old twins and their parents.
Med Sci Sports Exerc
28:
1479-1491,
1996[ISI][Medline].
22.
Montgomery, H,
Clarkson P,
Barnard M,
Bell J,
Brynes A,
Dollery C,
Hajnal J,
Hemingway H,
Mercer D,
Jarman P,
Marshall R,
Prasad K,
Rayson M,
Saeed N,
Talmud P,
Thomas L,
Jubb M,
World M,
and
Humphries S.
Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training.
Lancet
353:
541-545,
1999[ISI][Medline].
23.
Montgomery, HE,
Clarkson P,
Dollery CM,
Prasad K,
Losi MA,
Hemingway H,
Statters D,
Jubb M,
Girvain M,
Varnava A,
World M,
Deanfield J,
Talmud P,
McEwan JR,
McKenna WJ,
and
Humphries S.
Association of angiotensin-converting enzyme gene ID polymorphism with change in left ventricular mass in response to physical training.
Circulation
96:
741-747,
1997
24.
Montgomery, HE,
Marshall R,
Hemingway H,
Myerson S,
Clarkson P,
Dollery C,
Hayward M,
Holliman DE,
Jubb M,
World M,
Thomas EL,
Brynes AE,
Saeed N,
Barnard M,
Bell JD,
Prasad K,
Rayson M,
Talmud PJ,
and
Humphries SE.
Human gene for physical performance.
Nature
393:
221-222,
1998[Medline].
25.
Montoye, HJ,
and
Gayle R.
Familial relationships in maximal oxygen uptake.
Hum Biol
50:
241-249,
1978[ISI][Medline].
26.
Myerson, S,
Hemingway H,
Budget R,
Martin J,
Humphries S,
and
Montgomery H.
Human angiotensin I-converting enzyme gene and endurance performance.
J Appl Physiol
87:
1313-1316,
1999
27.
Palatini, P,
Bongiovi S,
Mario L,
Mormino P,
Raule G,
and
Pessina AC.
Effects of ACE inhibition on endurance exercise haemodynamics in trained subjects with mild hypertension.
Eur J Clin Pharmacol
48:
435-439,
1995[ISI][Medline].
28.
Predel, HG,
Rohden C,
Heine O,
Prinz U,
and
Rost RE.
ACE inhibition and physical exercise: studies on physical work capacity, energy metabolism, and maximum oxygen uptake in well-trained, healthy subjects.
J Cardiovasc Pharmacol
23:
S25-S28,
1994.
29.
Rankinen, T,
Perusse L,
Borecki I,
Chagnon YC,
Gagnon J,
Leon AS,
Skinner JS,
Wilmore JH,
Rao DC,
and
Bouchard C.
The Na+-K+-ATPase
2 gene and trainability of cardiorespiratory endurance: the HERITAGE Family Study.
J Appl Physiol
88:
346-351,
2000
30.
Rankinen, T,
Perusse L,
Gagnon J,
Chagnon YC,
Leon AS,
Skinner JS,
Wilmore JH,
Rao DC,
and
Bouchard C.
Angiotensin-converting enzyme ID polymorphism and trainability of the fitness phenotypes. the HERITAGE Family Study.
J Appl Physiol
88:
1029-1035,
2000
31.
Rauramaa, R,
Rankinen T,
Tuomainen P,
Vaisanen S,
and
Mercuri M.
Inverse relationship between cardiorespiratory fitness and carotid atherosclerosis.
Atherosclerosis
112:
213-221,
1995[ISI][Medline].
32.
Rigat, B,
Hubert C,
Alhenc-Gelas F,
Cambien F,
Corvol P,
and
Soubrier F.
An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.
J Clin Invest
86:
1343-1346,
1990.
33.
Rivera, MA,
Dionne FT,
Simoneau JA,
Perusse L,
Chagnon M,
Chagnon Y,
Gagnon J,
Leon AS,
Rao DC,
Skinner JS,
Wilmore JH,
and
Bouchard C.
Muscle-specific creatine kinase gene polymorphism and
O2 max in the HERITAGE Family Study.
Med Sci Sports Exerc
29:
1311-1317,
1997[ISI][Medline].
34.
Rivera, MA,
Perusse L,
Simoneau JA,
Gagnon J,
Dionne FT,
Leon AS,
Skinner JS,
Wilmore JH,
Province M,
Rao DC,
and
Bouchard C.
Linkage between a muscle-specific CK gene marker and
O2 max in the HERITAGE Family Study.
Med Sci Sports Exerc
31:
698-701,
1999[ISI][Medline].
35.
Rupert, JL,
Devine DV,
Monsalve MV,
and
Hochachka PW.
Angiotensin-converting enzyme (ACE) alleles in the Quechua, a high altitude South American native population.
Ann Hum Biol
26:
375-380,
1999[ISI][Medline].
36.
Samani, NJ,
Thompson JR,
O'Toole L,
Channer K,
and
Woods KL.
A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction.
Circulation
94:
708-712,
1996
37.
Sambrook, J,
Fritsch EF,
and
Maniatis T.
Molecular Cloning. Cold Spring Harbor, NY: Cold Spring Harbor, 1989.
38.
Schachter, F,
Faure-Delanef L,
Guenot F,
Rouger H,
Froguel P,
Lesueur-Ginot L,
and
Cohen D.
Genetic associations with human longevity at the APOE and ACE loci.
Nat Genet
6:
29-32,
1994[ISI][Medline].
39.
Staessen, JA,
Wang JG,
Ginocchio G,
Petrov V,
Saavedra AP,
Soubrier F,
Vlietinck R,
and
Fagard R.
The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk.
J Hypertens
15:
1579-1592,
1997[ISI][Medline].
40.
Sundet, JM,
Magnus P,
and
Tambs K.
The heritability of maximal aerobic power: a study of Norwegian twins.
Scand J Med Sci Sports
4:
181-185,
1994.
41.
Taylor, RR,
Mamotte CD,
Fallon K,
and
van Bockxmeer FM.
Elite athletes and the gene for angiotensin-converting enzyme.
J Appl Physiol
87:
1035-1037,
1999
42.
Tiret, L,
Rigat B,
Visvikis S,
Breda C,
Corvol P,
Cambien F,
and
Soubrier F.
Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels.
Am J Hum Genet
51:
197-205,
1992[ISI][Medline].
43.
Ueda, S,
Elliott HL,
Morton JJ,
and
Connell JM.
Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme.
Hypertension
25:
1266-1269,
1995
44.
Zee, RY,
Ridker PM,
Stampfer MJ,
Hennekens CH,
and
Lindpaintner K.
Prospective evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of stroke.
Circulation
99:
340-343,
1999
This article has been cited by other articles:
![]() |
M. J. Joyner and E. F. Coyle Endurance exercise performance: the physiology of champions J. Physiol., January 1, 2008; 586(1): 35 - 44. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Yamin, O. Amir, M. Sagiv, E. Attias, Y. Meckel, N. Eynon, M. Sagiv, and R. E. Amir ACE ID genotype affects blood creatine kinase response to eccentric exercise J Appl Physiol, December 1, 2007; 103(6): 2057 - 2061. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Amir, R. Amir, C. Yamin, E. Attias, N. Eynon, M. Sagiv, M. Sagiv, and Y. Meckel Human, Environmental & Exercise: The ACE deletion allele is associated with Israeli elite endurance athletes Exp Physiol, September 1, 2007; 92(5): 881 - 886. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. R Thompson and S. A Binder-Macleod Association of Genetic Factors With Selected Measures of Physical Performance Physical Therapy, April 1, 2006; 86(4): 585 - 591. [Full Text] [PDF] |
||||
![]() |
B Walpole, T D Noakes, M Collins, and R J Trent Growth hormone 1 (GH1) gene and performance and post-race rectal temperature during the South African Ironman triathlon * Commentary Br. J. Sports Med., February 1, 2006; 40(2): 145 - 150. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Carter, G. Onder, S. B. Kritchevsky, and M. Pahor Angiotensin-Converting Enzyme Inhibition Intervention in Elderly Persons: Effects on Body Composition and Physical Performance J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2005; 60(11): 1437 - 1446. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Grigorenko The Inherent Complexities of Gene-Environment Interactions J. Gerontol. B. Psychol. Sci. Soc. Sci., March 1, 2005; 60(suppl_Special_Issue_1): 53 - 64. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Williams, S. S. Dhamrait, P. T. E. Wootton, S. H. Day, E. Hawe, J. R. Payne, S. G. Myerson, M. World, R. Budgett, S. E. Humphries, et al. Bradykinin receptor gene variant and human physical performance J Appl Physiol, March 1, 2004; 96(3): 938 - 942. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Bahi, N. Koulmann, H. Sanchez, I. Momken, V. Veksler, A. X. Bigard, and R. Ventura-Clapier Does ACE inhibition enhance endurance performance and muscle energy metabolism in rats? J Appl Physiol, January 1, 2004; 96(1): 59 - 64. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Williams, S. H. Day, S. Dhamrait ;, and R. M. Fuentes ACE gene, physical activity, and physical fitness J Appl Physiol, October 1, 2002; 93(4): 1561 - 1562. [Full Text] [PDF] |
||||
![]() |
R. M. Fuentes, M. Perola, A. Nissinen, and J. Tuomilehto ACE gene and physical activity, blood pressure, and hypertension: a population study in Finland J Appl Physiol, June 1, 2002; 92(6): 2508 - 2512. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Montgomery, S. Dhamrait, J. R. Payne, A. Jones, D. Woods, L. A. Sonna, C. M. Lilly, M. A. Sharp, J. J. Knapik, and J. F. Patton ACE Genotype and Performance J Appl Physiol, April 1, 2002; 92(4): 1774 - 1777. [Full Text] [PDF] |
||||
![]() |
L. A. Sonna, M. A. Sharp, J. J. Knapik, M. Cullivan, K. C. Angel, J. F. Patton, and C. M. Lilly Angiotensin-converting enzyme genotype and physical performance during US Army basic training J Appl Physiol, September 1, 2001; 91(3): 1355 - 1363. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |